Britain and America have agreed to a important bilateral deal that will maintain zero levies on British drug exports entering the American market.
The Terms of the Accord
As part of the deal, the UK has pledged to increase spending on pharmaceuticals through the NHS. This pledge secures that import taxes on these key products will remain at nothing for a duration of the next three years.
This deal is in response to earlier warnings to dramatically increase duties on branded pharmaceutical products, with potential rates discussed as high as double the cost.
"This arrangement with the Britain strengthens the global environment for innovative medicines and establishes much-needed fairness to U.S.–U.K. drug exports," a release noted.
Commercial Importance
Medicines represent one of the the United Kingdom's most significant export categories to the US, which is by far the biggest destination for large UK drugmakers.
Trade data show that in the 12 months to the end of September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of all goods exports in that timeframe.
"This deal secures jobs, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for life sciences," a government official commented.
Specific NHS Changes
The agreement includes several key commitments from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to increase overall public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be capped at 15%. In the past, refunds topped twenty percent.
Broader Context
The deal takes place against a protracted tension between the sector and the British authorities over spending levels and regulatory access.
The disagreement were exacerbated by claims that US consumers were charged significantly more for the identical medicines than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
The Science Minister stated that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the past decade.
